Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Japanese H3 rocket fails during launch of navigation satellite (video) - 2Giude to Best Web based Learning Stage
- 3Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- 4The Best Traditional Music Arrangers in History
- 5Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- South Korea launches Earth-observation satellite on homegrown Nuri rocket
- Poland identifies two Ukrainian suspects in railway sabotage blast
- Single women risk rape and exploitation in search for better life in Europe
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- VPN Administrations for Online Protection
- 4 Coolers for Present day Kitchens
- Find the Future of Outsourcing: Exploring the Gig Economy
